OR YEHUDA, Israel, February 16, 2016 /PRNewswire/ --
ExceeMatrix is an innovative medical device company. The company is focused on providing a solution for ligaments and tendon repair, and the ACL implant is its first product to reach big animals studies.
The study was conducted on three goats which were implanted with the ExceeMatrix collagen based ACL implant. The surgery was done in a method used for humans with minor adjustments. Animals were observed for 6 weeks post implantation. The implants were implanted successfully and presented good mechanical function and infiltration of fibroblasts which is a sign of initial tissue regeneration.
Collagen is the most common protein in animals and humans, making up to 25-35% of the whole body protein content. Collagen is a structural protein, which is the main building block of connective tissues, including bone, skin, blood vessels, tendons, ligaments, etc.
ExceeMatrix is using a unique source of collagen fibers - soft corals. Collagen is known for its use in many medical applications for many years. This new collagen holds promising opportunities in new medical uses.
As opposed to mammalian collagen sources, the coral collagen does not go through breakdown, reconstitution and crosslinking. The development process of the coral collagen is cost effective and moves faster towards market approval. ExceeMatrix uses a customized purification process that allows the coral collagen to maintain its unique mechanical properties.
There were over 400,000 ACL reconstructions in the US last year, and 300,000 in Europe. This sport injury is becoming more and more prevalent due to the increase in the number of older athletes. Today, the grafts used for reconstruction are harvested from cadavers or from the patient themselves, causing a secondary site of surgery, pain and recovery. The ExceeMatrix ACL implant has the potential to overshadow the existing solutions, and offer a great, off the shelf solution without tissue harvesting and elimination of disease transmission.
The potential expenditures for ACL autografts and allografts are estimated to total over $3 billion worldwide. The market is looking for alternatives that do not require the surgical procedure of autografts or the use of cadaver source in allografts. ExceeMatrix holds an optimal solution by providing both the high tensile strength needed for ACL reconstruction, and regeneration induced by the collagen.
Gilad Karni, ExceeMatrix CEO: "The results are very encouraging, it is a great milestone for ExceeMatrix and the ACL implant is intended for clinical trial by 2018."